JenaValve Technology, Inc., a privately-held, venture-backed developer, manufacturer and marketer of transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, announced today that it has raised $62.5 million in a Series C venture round.

Through the kindness of Richard M. and Yvonne Hamlin, Summa Health System announced today the largest philanthropic gift in its organization’s history – a $4 million contribution for the creation of a hybrid cardiovascular operating room at Summa Akron City Hospital. In honor of the benefactors, Summa’s Center of Excellence building at 95 Arch Street in Akron will be renamed The Richard M. and Yvonne Hamlin Pavilion. The facility is home to numerous cardiopulmonary patient services as well as medical and surgical physician offices.

To improve clinical staff safety during interventional procedures and help monitor radiation dose, Toshiba America Medical Systems, Inc. has partnered with Unfors RaySafe, Inc. to offer a new dose monitoring and management tool for Infinix™-i cardiovascular X-ray systems. The Unfors RaySafe i2 displays real-time dose exposure information, helping to make exams safer for all clinical staff.

A new book, The Heart of Leonardo, features all of Leonardo's drawings on the heart and its physiology, accompanied by translations of his accompanying notes.

Enhancing its product leadership team, Toshiba America Medical Systems, Inc. has named David Sloop director, X-ray Vascular Business Unit. Sloop will be responsible for implementing strategic marketing plans to drive growth and profitability of Toshiba’s X-ray Vascular product line.

Boston Scientific Corporation (NYSE: BSX) has received U.S. Food and Drug Administration 510(k) clearance and CE Mark approval for the Guidezilla™ Guide Extension Catheter and has launched the device in the U.S. and Europe.

STENTYS, a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), announced today that it received approval from its European Notified Body to expand the CE Mark indications of the Self-Apposing stent.

Inspired by a genetic mutation that keeps low-density lipoprotein levels extremely low, three pharmaceutical companies are developing cholesterol drugs that mimic the trait. The New York Times described how drug makers are scurrying to get these potential blockbusters to market.